30 Oct 2025 | 5 Mins Read
Eli Lilly raises full-year profit forecast due to Zepbound demand
Flipitmoney
Eli Lilly raised full-year profit and revenue forecasts, driven by strong demand for its weight-loss and diabetes drugs Zepbound and Mounjaro. Shares surged 7% in pre-market trading after beating Q3 earnings expectations. Adjusted profit is now forecast at $23.00-$23.70 per share, surpassing previous guidance. Zepbound sales reached $3.6 billion in Q3, outperforming estimates.